294 related articles for article (PubMed ID: 32084434)
1. The mechanisms of lysophosphatidylcholine in the development of diseases.
Liu P; Zhu W; Chen C; Yan B; Zhu L; Chen X; Peng C
Life Sci; 2020 Apr; 247():117443. PubMed ID: 32084434
[TBL] [Abstract][Full Text] [Related]
2. Lysophosphatidylcholine: Potential Target for the Treatment of Chronic Pain.
Ren J; Lin J; Yu L; Yan M
Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35955410
[TBL] [Abstract][Full Text] [Related]
3. An Updated Review of Lysophosphatidylcholine Metabolism in Human Diseases.
Law SH; Chan ML; Marathe GK; Parveen F; Chen CH; Ke LY
Int J Mol Sci; 2019 Mar; 20(5):. PubMed ID: 30845751
[TBL] [Abstract][Full Text] [Related]
4. Annexin A5 inhibits atherogenic and pro-inflammatory effects of lysophosphatidylcholine.
Domeij H; Hua X; Su J; Bäcklund A; Yan Z; Frostegård AG; Haeggström JZ; Modéer T; Frostegård J
Prostaglandins Other Lipid Mediat; 2013 Oct; 106():72-8. PubMed ID: 23391726
[TBL] [Abstract][Full Text] [Related]
5. Radiation-induced lipoprotein-associated phospholipase A2 increases lysophosphatidylcholine and induces endothelial cell damage.
Kim SR; Heo JI; Park JW; Kang CM; Kim KS
Toxicology; 2021 Jun; 458():152841. PubMed ID: 34216699
[TBL] [Abstract][Full Text] [Related]
6. Lysophosphatidylcholine and secretory phospholipase A2 in vascular disease: mediators of endothelial dysfunction and atherosclerosis.
Kougias P; Chai H; Lin PH; Lumsden AB; Yao Q; Chen C
Med Sci Monit; 2006 Jan; 12(1):RA5-16. PubMed ID: 16369478
[TBL] [Abstract][Full Text] [Related]
7. Metabolism and atherogenic disease association of lysophosphatidylcholine.
Schmitz G; Ruebsaamen K
Atherosclerosis; 2010 Jan; 208(1):10-8. PubMed ID: 19570538
[TBL] [Abstract][Full Text] [Related]
8. Role of lysophosphatidylcholine (LPC) in atherosclerosis.
Matsumoto T; Kobayashi T; Kamata K
Curr Med Chem; 2007; 14(30):3209-20. PubMed ID: 18220755
[TBL] [Abstract][Full Text] [Related]
9. Comparative toxicity of oxidatively modified low-density lipoprotein and lysophosphatidylcholine in cultured vascular endothelial cells.
Naito M; Yamada K; Hayashi T; Asai K; Yoshimine N; Iguchi A
Heart Vessels; 1994; 9(4):183-7. PubMed ID: 7961295
[TBL] [Abstract][Full Text] [Related]
10. Lysophosphatidylcholine induces inflammatory activation of human coronary artery smooth muscle cells.
Aiyar N; Disa J; Ao Z; Ju H; Nerurkar S; Willette RN; Macphee CH; Johns DG; Douglas SA
Mol Cell Biochem; 2007 Jan; 295(1-2):113-20. PubMed ID: 16896535
[TBL] [Abstract][Full Text] [Related]
11. Lysophosphatidylcholine promotes SREBP-2 activation via rapid cholesterol efflux and SREBP-2-independent cytokine release in human endothelial cells.
Morita M; Sekine A; Urano Y; Nishimura T; Takabe W; Arai H; Hamakubo T; Kodama T; Noguchi N
J Biochem; 2015 Oct; 158(4):331-8. PubMed ID: 25998247
[TBL] [Abstract][Full Text] [Related]
12. Oxidative modification of low-density lipoproteins and the inhibition of relaxations mediated by endothelium-derived nitric oxide in rabbit aorta.
Plane F; Bruckdorfer KR; Kerr P; Steuer A; Jacobs M
Br J Pharmacol; 1992 Jan; 105(1):216-22. PubMed ID: 1596684
[TBL] [Abstract][Full Text] [Related]
13. Lysophosphatidylcholine and 7-oxocholesterol modulate Ca2+ signals and inhibit the phosphorylation of endothelial NO synthase and cytosolic phospholipase A2.
Millanvoye-Van Brussel E; Topal G; Brunet A; Do Pham T; Deckert V; Rendu F; David-Dufilho M
Biochem J; 2004 Jun; 380(Pt 2):533-9. PubMed ID: 14992685
[TBL] [Abstract][Full Text] [Related]
14. [Metformin prevents non-alcoholic fatty liver disease in rats: role of phospholipase A2/lysophosphatidylcholine lipoapoptosis pathway in hepatocytes].
Huang Y; Fu JF; Shi HB; Liu LR
Zhonghua Er Ke Za Zhi; 2011 Feb; 49(2):139-45. PubMed ID: 21426695
[TBL] [Abstract][Full Text] [Related]
15. Hydrolysis of low-density lipoprotein phospholipids in arterial smooth muscle cells.
Ishikawa Y; Nishide T; Sasaki N; Shirai K; Saito Y; Yoshida S
Biochim Biophys Acta; 1988 Jul; 961(2):170-6. PubMed ID: 3390454
[TBL] [Abstract][Full Text] [Related]
16. Phosphatidylcholine and phosphatidylethanolamine plasmalogens in lipid loaded human macrophages.
Wallner S; Orsó E; Grandl M; Konovalova T; Liebisch G; Schmitz G
PLoS One; 2018; 13(10):e0205706. PubMed ID: 30308051
[TBL] [Abstract][Full Text] [Related]
17. The atherogenic actions of LPC on vascular smooth muscle cells and its LPA receptor mediated mechanism.
Bao L; Qi J; Wang YW; Xi Q; Tserennadmid T; Zhao PF; Qi J; Damirin A
Biochem Biophys Res Commun; 2018 Sep; 503(3):1911-1918. PubMed ID: 30064908
[TBL] [Abstract][Full Text] [Related]
18. Lysophosphatidylcholine (LPC) induces proinflammatory cytokines by a platelet-activating factor (PAF) receptor-dependent mechanism.
Huang YH; Schäfer-Elinder L; Wu R; Claesson HE; Frostegård J
Clin Exp Immunol; 1999 May; 116(2):326-31. PubMed ID: 10337026
[TBL] [Abstract][Full Text] [Related]
19. Synthetic peptide (P-21) derived from Asp-hemolysin inhibits the induction of apoptosis on HUVECs by lysophosphatidylcholine.
Tsutsumi H; Kumagai T; Naitoo S; Ebina K; Yokota K
Biol Pharm Bull; 2006 May; 29(5):907-10. PubMed ID: 16651717
[TBL] [Abstract][Full Text] [Related]
20. Lysophosphatidylcholine is involved in the antigenicity of oxidized LDL.
Wu R; Huang YH; Elinder LS; Frostegård J
Arterioscler Thromb Vasc Biol; 1998 Apr; 18(4):626-30. PubMed ID: 9555869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
